The director of the Mario Lemieux Center for Blood Cancers at UPMC Hillman Cancer Center discussed strategies to manage AEs associated with CAR T therapy.
This content originally appeared on our sister site, Cancer Network.
Cancer Network spoke with Mounzer Agha, MD, of the University of Pittsburgh School of Medicine Hillman Cancer Center, about the encouraging safety profile reported from the CARTITUDE-2 trial investigating ciltacabtagene autoleucel (cilta-cel) for patients with previously treated multiple myeloma at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting.1
The strategies he detailed included reducing neurologic adverse events by use of more effective bridging therapy, frequent assessment of CAR T-cell–related immune effector cell-associated neurotoxicity syndrome, and handwriting assignments to detectmicrographia, among others.2
Transcription:
The most important thing I’d really like to emphasize is that in CARTITUDE-2, we showed an excellent safety profile.1 So, unlike with CARTITUDE-1 where we encountered the cognitive and neuro-movement disorders, we [do] not seen that now anymore because we applied the mitigation strategies. By eliminating that, it opens the door to apply this treatment in earlier treatment settings.
Choosing the Right Patient Populations for CAR-T Clinical Trials in Neurologic Autoimmune Disease
March 21st 2024Bruce Cree, MD, PhD, MAS, a professor of neurology and the clinical research director of the University of California San Francisco (UCSF) Multiple Sclerosis Center discussed considerations for evaluating CAR-T in patients most likely to obtain meaningful benefit.